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Synops~s 
Differentla1 regulation of p73 by vlral oncogenes and its ~mpl~ca t~ons  for
therapeutics 
p53 IS one of the most extensively studied genes in cancer biology It IS a 
sequence-spec~fic DNA-binding transcnption factor It induces the transcnption of a 
vanety of genes that regulate diverse cellular processes llke cell cycle progression, 
apoptosis, genetic stability and angiogenesis It is also a cntlcal component of pathways 
mediating cellular responses to aberrant growth s~gnals as well as genotoxic stresses like 
DNA damage, hypoxla, etc For these reasons it has been differently descnbed as 
"Gztardtan of the Genorne" and "Cellular Gatekeeper for growth and dzvzszon" 
Two p53 homologs viz p63 and p73 have been identified p73 is located at 
chromosome lp36 It encodes several alternately spliced products l~ke  p73a, p73P, 
p73y, etc p73 has high homology with the tumor suppressor p53 with respect to its 
DNA binding, transactivation and oligomensat~on domains When exogenously 
overexpressed, p73 can transactivate several of p53 target genes like p2 1 WAFIICIPI, mdm2, 
bax etc thereby inducing cell cycle arrest or apoptosis These facts suggest that p73 may 
function as a tumor suppressor However, mice canylng homozygous deletion of p73 do 
not show increased susceptibility to spontaneous tumongenesls but camed defects like 
hippocampal dysgenesis, hydrocephalus, chronic infect~on and sensory pathway 
abnormalities suggestive of a role in neurogenesis, sensory pathways and homeostatic 
control for p73. Viral oncogenes SV40 T antigen and HPV 16 E6 do not inactivate p73, 
unlike p53 Moreover, p73 is rarely mutated in human cancers l h s  raises a question 
whether p73 has any role m the process of transformation at all While t h ~ s  work was 
under progress, there were reports, which showed that p73 plays a role in E2F-medrated 
p53 ~ndependent apoptosis It was also found to play a crucial role in DNA damage 
11 
induced p53-mediated apoptosis Moreover p73 has also been established as an 
important determinant for chemosensitivity of cancer cells 
This study was carned to functionally charactenze p73 and to evaluate its 
therapeutic potential The maln objectives of this study were 
1 Regulat~on of p73 by adenovirus oncogene E1A 
2 Construction and charactenzation of a recombinant adenovirus expressing p73P 
as an anti-cancer agent 
3 p73 based gene therapy for cervical cancer 
Viral oncogenes serve as a useful tool for the study of tumor suppressors E1A 1s 
a transforming oncogene of the adenovirus E1A isolated from different adenoviral 
serotypes have been found to have three conserved repons viz. CR1 (aa 40-SO), CR2 (aa 
121-139) and CR3 (aa 140-1 80) 12s ElA and 13s E1A are the two major alternately 
spliced products of El  A 12s E1A does not have CR3 doman but the sequences in it are 
necessary and sufficient for transformatron ElA blnds to two groups of cellular proteins 
vlz 1) p300lCBP family of transactivators using its N-tennus and CRl domain, 2)  
Retrnoblastoma family using its CR1 and CR2 domains p53 requires p300lCBP as 
coactivator for rts transact~vation finction When ElA blnds p300/CBP, it inhibrts p53 
transactivation function thereby overcoming p53 regulated cell cycle checkpoint 
Similarly ElA binds Rb to overcome Rb mediated cell cycle checkpoint Thus ElA is 
able to cause cellular transformation by targeting both p53 and Rb Since E1A ihlbits 
p53 transactivation function and p73 has significant homology with p53, we tned to 
explore the effect of E 1 A on p73 Our results show that El  A inlubits the transactivation 
function of p73a and p73P, two different splice vanants of p73 ElA mutant del2-36, 
which does not brnd to p300/CBP family of transcriptional coactivators, faled to inhibit 
p73 transact~vation function, while E1A mutant del CR2, whlch does not bind to 
iri 
retinoblastoma protein, inhibited the p73-mediated transactivation very efficiently This 
shows that the p300lCBP binding region of ElA is lnvolved In inhibiting p73 
transactivation fbnction Additional expenrnents revealed that E1A does not affect the 
sequence-specific DNA-binding activity of p73 but targets only the N- and C-terminal 
transactivatlon domains Our results also demonstrate that E1A can inhibit p73-mediated 
transactivation of its natural target gene p21 thereby overcoming p73 mediated cell cycle 
arrest We also found that endogenous p73 levels get induced in response to E1A 
expression thereby making it essential for ElA to inhibit p73 function for successful 
transforrnatlon These results suggest that p73 has a role to play as a tumor suppressor 
Development of gene therapy technologies is very important for the treatment of 
human cancers and the tumor suppressor genes have been widely exploited for this 
purpose Significant knowledge about the anti-tumor mechanisms of p53 has made it 
one of the most used tumor suppressor genes for this purpose However, p53-based gene 
therapy 1s not suitable in certain cases where hc t lonal  lnactivatlon of p53 takes place 
like amplification of mdm-2, mutational inactivation of p14ARF etc Moreover, in climcal 
tnals the restoration of wild type p53 gene does not always lead to tumor regression or 
tumor growth inhibition suggesting resistance of some tumors to exogenous p53 Hence 
it rases the poss~bility that p73, a p53 hornolog, slmllar to p53 in structure and function 
could be used as an alternative For this purpose we constructed a replication-deficient 
recombinant adenovirus expressing p73 P (Ad-p73) and checked its abllity to lnbibit the 
growth of a panel of human cancer cell llnes of diverse tissue ongm Our results clearly 
show that Ad-p73 can Infect a vanety of human cancer cell lines resulting m the 
overexpression of p73P protein and ~ t s  target gene p21 Infection wrth Ad-p73 resulted 
m potent cytotox~clty m all the cell llnes tested The mechanrsm of p73-induced 
cytotoxicity In these cell llnes was found to be a combination of cell cycle arrest and 
1v 
induction of apoptosis Moreover, Ad-p73 enhanced the chernosensitivity of cancer cells 
to commonly used anti-cancer drug adnamycin Furthermore, Ad-p73 was more 
effic~ent han Ad-p53 (a replication-deficient recombinant adenovirus expressing p53) in 
enhancing the chemosensitivity of mutant p53 harboring cells These results suggest that 
Ad-p73 could be developed as a gene therapy agent aga~nst cancer 
Cervical cancer is the second most common malignancy in women worldw~de 
The overall survlval rate of cervical cancer patients is 40% Human pap~lloma vlrus has 
been strongly irnpl~cated as a causative agent for cervical cancer Of its gene products, 
E6 binds to and targets the p53 protein for ubiqmtin/proteasome dependent degradation 
making such cancers resistant to p53 gene therapy For this reason p53-based therapy is 
not suitable for treatment of cervical cancer Although p73 is similar to p53 In structure 
and function, ~t IS not targeted for degradation by E6 Thus it ralses the possibil~ty that 
p73 could be used for gene therapy of cervlcal cancer To explore this poss~bility we 
adopted both an zn vztro and an tn vzvo approach In the zn vztro approach, we used. a) 
Three E6 stable cell lines, each of different tissue ongm, and b) Four cerv~cal cancer cell 
lines out of which three are HPV pos~tive In the m vzvo approach, we used nude mice 
xenograft tumor models In the zn vztro approach, we found that Ad-p73 exhlbits potent 
cytotoxicity in E6 stable cell lines as well as in HPV positive cervlcal cancer cell lines 
unlike Ad-p53 because of stable expression of fbctional p73 in those cell lines In the 
In vzvo approach, we found that Ad-p73 was able to efficiently ~nhrbit he turnorogemcity 
as well as the growth of xenograft tumors of both E6 expressing cells (HCT116 E6) and 
HPV-positive cervical cancer cell llne (HeLa) unlike Ad-p53 The analysis of the tumors 
revealed that both p53 and p73 are transcnbed from the respective adenov~ruses but only 
p73 protein is stable and functionally active in the tumors as revealed by p21 WAFlICIPl 
expression and induct~on of apoptosis Hence our results demonstrate that Ad-p73 could 
be a candidate for treatment of cervical cancer 
